Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)

J. M.R. Van der Meer; R. J.A. Maas; K. Guldevall; K. Klarenaar; P. K.J.D. De Jonge; J. S. Hoogstad-van Evert; A. B. van der Waart; J. Cany; J. T. Safrit; J. H. Lee; E. Wagena; P. Friedl; B. Önfelt; L. F. Massuger; N. P.M. Schaap; J. H. Jansen; W. Hobo; H. Dolstra

doi:10.1007/s00262-021-03049-5

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)

J. M.R. Van der Meer, R. J.A. Maas, K. Guldevall, K. Klarenaar, P. K.J.D. De Jonge, J. S. Hoogstad-van Evert, A. B. van der Waart, J. Cany, J. T. Safrit, J. H. Lee, E. Wagena, P. Friedl, B. Önfelt, L. F. Massuger, N. P.M. Schaap, J. H. Jansen, W. Hobo, H. Dolstra

Genitourinary Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Unfortunately, the given name and family name of the sixth author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as ‘‘Evert, JSH’’ in Pubmed. The correct given name is J.S. and family name is Hoogstad-van Evert.

Original language	English (US)
Pages (from-to)	3367
Number of pages	1
Journal	Cancer Immunology, Immunotherapy
Volume	70
Issue number	11
DOIs	https://doi.org/10.1007/s00262-021-03049-5
State	Published - Nov 2021

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Research Animal Support Facility
Small Animal Imaging Facility

Access to Document

10.1007/s00262-021-03049-5

Fingerprint

Dive into the research topics of 'Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)'. Together they form a unique fingerprint.

Cite this

Van der Meer, J. M. R., Maas, R. J. A., Guldevall, K., Klarenaar, K., De Jonge, P. K. J. D., Hoogstad-van Evert, J. S., van der Waart, A. B., Cany, J., Safrit, J. T., Lee, J. H., Wagena, E., Friedl, P., Önfelt, B., Massuger, L. F., Schaap, N. P. M., Jansen, J. H., Hobo, W., & Dolstra, H. (2021). Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8). Cancer Immunology, Immunotherapy, 70(11), 3367. https://doi.org/10.1007/s00262-021-03049-5

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8). / Van der Meer, J. M.R.; Maas, R. J.A.; Guldevall, K. et al.
In: Cancer Immunology, Immunotherapy, Vol. 70, No. 11, 11.2021, p. 3367.

Research output: Contribution to journal › Comment/debate › peer-review

Van der Meer, JMR, Maas, RJA, Guldevall, K, Klarenaar, K, De Jonge, PKJD, Hoogstad-van Evert, JS, van der Waart, AB, Cany, J, Safrit, JT, Lee, JH, Wagena, E, Friedl, P, Önfelt, B, Massuger, LF, Schaap, NPM, Jansen, JH, Hobo, W & Dolstra, H 2021, 'Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)', Cancer Immunology, Immunotherapy, vol. 70, no. 11, pp. 3367. https://doi.org/10.1007/s00262-021-03049-5

Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, De Jonge PKJD, Hoogstad-van Evert JS et al. Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8). Cancer Immunology, Immunotherapy. 2021 Nov;70(11):3367. doi: 10.1007/s00262-021-03049-5

Van der Meer, J. M.R. ; Maas, R. J.A. ; Guldevall, K. et al. / Correction to : IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8). In: Cancer Immunology, Immunotherapy. 2021 ; Vol. 70, No. 11. pp. 3367.

@article{1dee20a230d74b9cabd9dd4a33d301e5,

title = "Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)",

abstract = "Unfortunately, the given name and family name of the sixth author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as {\textquoteleft}{\textquoteleft}Evert, JSH{\textquoteright}{\textquoteright} in Pubmed. The correct given name is J.S. and family name is Hoogstad-van Evert.",

author = "{Van der Meer}, {J. M.R.} and Maas, {R. J.A.} and K. Guldevall and K. Klarenaar and {De Jonge}, {P. K.J.D.} and {Hoogstad-van Evert}, {J. S.} and {van der Waart}, {A. B.} and J. Cany and Safrit, {J. T.} and Lee, {J. H.} and E. Wagena and P. Friedl and B. {\"O}nfelt and Massuger, {L. F.} and Schaap, {N. P.M.} and Jansen, {J. H.} and W. Hobo and H. Dolstra",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2021",

year = "2021",

month = nov,

doi = "10.1007/s00262-021-03049-5",

language = "English (US)",

volume = "70",

pages = "3367",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

TY - JOUR

T1 - Correction to

T2 - IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)

AU - Van der Meer, J. M.R.

AU - Maas, R. J.A.

AU - Guldevall, K.

AU - Klarenaar, K.

AU - De Jonge, P. K.J.D.

AU - Hoogstad-van Evert, J. S.

AU - van der Waart, A. B.

AU - Cany, J.

AU - Safrit, J. T.

AU - Lee, J. H.

AU - Wagena, E.

AU - Friedl, P.

AU - Önfelt, B.

AU - Massuger, L. F.

AU - Schaap, N. P.M.

AU - Jansen, J. H.

AU - Hobo, W.

AU - Dolstra, H.

PY - 2021/11

Y1 - 2021/11

N2 - Unfortunately, the given name and family name of the sixth author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as ‘‘Evert, JSH’’ in Pubmed. The correct given name is J.S. and family name is Hoogstad-van Evert.

AB - Unfortunately, the given name and family name of the sixth author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as ‘‘Evert, JSH’’ in Pubmed. The correct given name is J.S. and family name is Hoogstad-van Evert.

UR - http://www.scopus.com/inward/record.url?scp=85114867277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114867277&partnerID=8YFLogxK

U2 - 10.1007/s00262-021-03049-5

DO - 10.1007/s00262-021-03049-5

M3 - Comment/debate

C2 - 34524494

AN - SCOPUS:85114867277

SN - 0340-7004

VL - 70

SP - 3367

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 11

ER -

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells (Cancer Immunology, Immunotherapy, (2021), 70, 5, (1305-1321), 10.1007/s00262-020-02749-8)

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this